Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986301 |
| Synonyms | |
| Therapy Description |
BMS-986301 acts as an agonist of Stimulator of interferon genes (STING1), which potentially results in improved antitumor immune response (PMID: 30400822). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986301 | BMS986301|BMS 986301 | STING1 Agonist 21 | BMS-986301 acts as an agonist of Stimulator of interferon genes (STING1), which potentially results in improved antitumor immune response (PMID: 30400822). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03956680 | Phase I | Ipilimumab + Nivolumab BMS-986301 | An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers | Completed | USA | CAN | 0 |